# Frailty in Hepatocellular Carcinoma: An Unsettled Clinical Challenge

## TL;DR

Frailty in patients with liver cancer is a growing concern, and better ways to measure it could improve treatment decisions.

## Contribution

This review highlights the clinical relevance of frailty in hepatocellular carcinoma and identifies gaps in standardized assessment tools.

## Key findings

- Frailty in HCC patients may be influenced by cirrhosis and tumor burden, not just age.
- The Liver Frailty Index is a validated tool for liver transplant candidates but lacks standardization for HCC.
- Current evidence on how to use frailty assessments to guide HCC treatment decisions is limited.

## Abstract

Frailty describes a state of reduced physiological reserve that increases vulnerability to adverse health outcomes. Although traditionally associated with older adults, frailty is increasingly recognized in younger patients with chronic diseases, including those with hepatocellular carcinoma (HCC). Patients with HCC often have underlying liver cirrhosis, which may contribute to frailty independently of age and tumor burden. This review summarizes current evidence on frailty in HCC, highlighting available assessment tools, their clinical relevance, and existing knowledge gaps. Understanding and measuring frailty in this population may improve prognostic stratification and support more individualized treatment decisions, although standardized approaches and dedicated studies are still lacking.

Frailty is a clinical syndrome originally described in geriatrics but increasingly recognized across multiple medical fields. A wide variety of clinical tools have been developed to identify and quantify frailty in different contexts. In oncology, the Performance Status (PS) has long guided therapeutic decisions; however, with the evolution of cancer treatments and the aging of the patient population, a more comprehensive assessment of frailty is emerging as a valuable clinical tool. In patients with cirrhosis, frailty may manifest earlier than in the general population, and the Liver Frailty Index (LFI) has gained prominence as a validated measure among liver transplant candidates. Individuals with hepatocellular carcinoma (HCC) may exhibit frailty due to both the underlying cirrhosis and tumor burden. Nonetheless, evidence on the role of frailty in guiding treatment decisions for HCC remains limited, and standardized assessment tools are still lacking to optimize patient stratification and therapeutic allocation.